title: A comparison of the potency of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) to counteract soman-induced neurotoxicity in rats.
abstract: The neuroprotective effects of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in combination with atropine in rats poisoned with soman were studied. The soman-induced neurotoxicity was monitored using a functional observational battery at 24 h and 7 days after soman challenge. The results indicate that the oxime HI-6 combined with atropine seems to be an effective antidote for a decrease in soman-induced neurotoxicity, whereas the ability of both newly developed oximes (K074, K075) as well as obidoxime to counteract soman-induced acute neurotoxicity is negligible. Due to the absence of their neuroprotective potency, both newly developed oximes are not suitable oximes for antidotal treatment after exposure to soman. The oxime HI-6 is still the best acetylcholinesterase reactivator for the antidotal treatment of acute poisonings with soman.
authors: Department of Toxicology, Faculty of Military Health Sciences, Hradec Kralove, Czech Republic. kassa@pmfhk.cz
authors: Jiri
authors: J
authors: Kassa
authors: Jana
authors: J
authors: Karasova
mesh_terms: D000818:Animals; D000931:Antidotes / Q000494:pharmacology* / Q000627:therapeutic use; D001285:Atropine / Q000494:pharmacology / Q000627:therapeutic use; D001341:Autonomic Nervous System / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D002073:Butanes / Q000494:pharmacology / Q000627:therapeutic use; D002619:Chemical Warfare Agents / Q000633:toxicity; D002801:Cholinesterase Reactivators / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018696:Neuroprotective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D020258:Neurotoxicity Syndromes / Q000188:drug therapy*; D009768:Obidoxime Chloride / Q000494:pharmacology / Q000627:therapeutic use; D010091:Oximes / Q000494:pharmacology / Q000627:therapeutic use; D011726:Pyridinium Compounds / Q000494:pharmacology / Q000627:therapeutic use; D051381:Rats; D017208:Rats, Wistar; D012999:Soman / Q000633:toxicity; D013329:Structure-Activity Relationship
chemical_list: C515196:1,4-bis(4-hydroxyiminomethylpyridinium)butane dibromide; D000931:Antidotes; D002073:Butanes; D002619:Chemical Warfare Agents; D002801:Cholinesterase Reactivators; C518856:K075 compound; D018696:Neuroprotective Agents; D010091:Oximes; D011726:Pyridinium Compounds; D009768:Obidoxime Chloride; D001285:Atropine; D012999:Soman; C022870:asoxime chloride